A Single-dose, Open-label, Randomized, 4-way Crossover Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs GDC 0276 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Genentech
- 24 Feb 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 01 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2016.
- 01 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.